Overall Survival in Aggressive B-cell Lymphomas is Dependent on the Accumulation of Alterations in P53, P16, and P27

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2001 Jul 5

PMID 11438467

Citations 17

Authors

M Sanchez-Beato

A I Saez

I C Navas

P Algara

M Sol Mateo

R Villuendas

F Camacho

A Sanchez-Aguilera

E Sanchez

M A Piris

Affiliations

Soon will be listed here.

Abstract

Different studies have already shown that the isolated inactivation of p21, p16, or p27 cyclin-dependent kinase inhibitors (CKIs) is associated with increased growth fraction, tumor progression, or decreased overall survival in cases of non-Hodgkin's lymphoma. In this study we linked molecular study of the p53 and p16 genes with immunohistochemical analysis of p27 expression in a group of aggressive B-cell lymphomas [large B-cell lymphomas (LBCLs) and Burkitt's lymphomas]. This was done to analyze the relationship between p53 and p16 silencing, p27 anomalous overexpression, and clinical follow-up, testing the hypothesis that the accumulation of CKI alterations could confer to the tumors a higher aggressivity. In a group of 62 patients, p53 inactivation as a result of mutation was observed in 11 cases (18%) and p16 silencing was seen in 27 cases (43.5%) as a result of methylation (20 of 62), 9p21 deletion (7 of 44), or p16 mutation (2 of 62). The simultaneous inactivation of p53 and p16 was detected exclusively in five LBCL cases. Anomalous expression of p27, which has been proven to be associated with the absence of p27/CDK2 complexes and the formation of p27/cyclin D3 complexes where p27 is inactivated, was detected in 19 of 61 cases (31%). Cases characterized by p27 anomalous expression display concurrent inactivation of p21 (provided by p53 mutations) and/or p16 CKIs in 11 of 14 LBCL cases (P = 0.040). When the relationship between the association of inactivated CKIs and overall survival was considered, a significant relationship was found between a lower overall survival probability and an increased number of inactivated CKIs in LBCL cases, with the worst prognosis for the cases displaying concurrent p53, p16, and p27 alterations. This proves that simultaneous inactivation of different tumor suppressor pathways does indeed take place, and that tumor aggressiveness takes advantage of this CKI-concerted silencing. In this same series of data, Burkitt's lymphoma patients seem to behave in a different way than LBCLs, with p53 and p16 alteration being mutually exclusive and the association with p27 anomalous expression not being clinically significant. These facts seem to support that the additive effect of the inactivation of different CKIs could be dependent of the histological type.

Citing Articles

Concurrent and Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.

Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K Cancers (Basel). 2020; 12(8).

PMID: 32751805 PMC: 7466084. DOI: 10.3390/cancers12082120.

The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma.

Shawky S, El-Borai M, Khaled H, Guda I, Mohanad M, Abdellateif M Mol Biol Rep. 2019; 46(4):4063-4076.

PMID: 31093876 DOI: 10.1007/s11033-019-04856-x.

Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.

Lopez C, Kleinheinz K, Aukema S, Rohde M, Bernhart S, Hubschmann D Nat Commun. 2019; 10(1):1459.

PMID: 30926794 PMC: 6440956. DOI: 10.1038/s41467-019-08578-3.

Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.

Krajnovic M, Perunicic Jovanovic M, Mihaljevic B, Andelic B, Tarabar O, Knezevic-Usaj S Clin Transl Sci. 2014; 7(5):384-90.

PMID: 24815848 PMC: 5350871. DOI: 10.1111/cts.12162.

Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.

Krajnovic M, Radojkovic M, Davidovic R, Dimitrijevic B, Krtolica K Med Oncol. 2013; 30(1):441.

PMID: 23275143 DOI: 10.1007/s12032-012-0441-3.

References

Markl I, Jones P . Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res. 1998; 58(23):5348-53. View

Stranks G, Height S, Mitchell P, Jadayel D, Yuille M, De Lord C . Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood. 1995; 85(4):893-901. View

Sharpless N, DePinho R . The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev. 1999; 9(1):22-30. DOI: 10.1016/s0959-437x(99)80004-5. View

Sol Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez-Delgado B . Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas. Mol Pathol. 1999; 51(5):262-7. PMC: 395649. DOI: 10.1136/mp.51.5.262. View

Mitra J, Dai C, Somasundaram K, El-Deiry W, Satyamoorthy K, Herlyn M . Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol. 1999; 19(5):3916-28. PMC: 84249. DOI: 10.1128/MCB.19.5.3916. View

Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez P . 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999; 154(5):1583-9. PMC: 1866606. DOI: 10.1016/S0002-9440(10)65411-9. View

Greenberg R, Chin L, Femino A, Lee K, Gottlieb G, Singer R . Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 1999; 97(4):515-25. DOI: 10.1016/s0092-8674(00)80761-8. View

Sanchez-Beato M, Camacho F, Martinez-Montero J, Saez A, Villuendas R, Sanchez-Verde L . Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood. 1999; 94(2):765-72. View

Saez A, Sanchez E, Sanchez-Beato M, Cruz M, Chacon I, Munoz E . p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome. Br J Cancer. 1999; 80(9):1427-34. PMC: 2363083. DOI: 10.1038/sj.bjc.6690539. View

10.

Baur A, Shaw P, Burri N, Delacretaz F, Bosman F, Chaubert P . Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood. 1999; 94(5):1773-81. View

11.

Perez-Roger I, Kim S, Griffiths B, Sewing A, Land H . Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999; 18(19):5310-20. PMC: 1171601. DOI: 10.1093/emboj/18.19.5310. View

12.

Bouchard C, Thieke K, Maier A, Saffrich R, Ansorge W, Reed S . Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999; 18(19):5321-33. PMC: 1171602. DOI: 10.1093/emboj/18.19.5321. View

13.

Levine A, Momand J . Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta. 1990; 1032(1):119-36. DOI: 10.1016/0304-419x(90)90015-s. View

14.

Nobori T, Miura K, Wu D, Lois A, Takabayashi K, Carson D . Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994; 368(6473):753-6. DOI: 10.1038/368753a0. View

15.

Kamb A, Gruis N, Liu Q, Harshman K, Tavtigian S, STOCKERT E . A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994; 264(5157):436-40. DOI: 10.1126/science.8153634. View

16.

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

17.

Schmitt C, McCurrach M, de Stanchina E, Wallace-Brodeur R, Lowe S . INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999; 13(20):2670-7. PMC: 317110. DOI: 10.1101/gad.13.20.2670. View

18.

Barnouin K, Fredersdorf S, Eddaoudi A, Mittnacht S, Pan L, Du M . Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene. 1999; 18(46):6388-97. DOI: 10.1038/sj.onc.1203162. View

19.

Garcia J, Villuendas R, Algara P, Saez A, Sanchez-Verde L, Martinez-Montero J . Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest. 2000; 79(12):1453-9. View

20.

Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S . INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol. 2000; 156(6):1987-96. PMC: 1850083. DOI: 10.1016/S0002-9440(10)65071-7. View